Health Affairs July 31, 2019
Rachel Sachs

This morning, the Trump administration announced a plan that, if eventually finalized, would enable the importation of prescription drugs, primarily from Canada. This plan is part of the administration’s overall agenda to bring down prescription drug prices, and like the rest of that agenda it faces a number of potential roadblocks before it can be implemented.

In this post, I summarize the existing legal authority on the issue of drug importation and situate it within the administration’s broader efforts to lower prescription drug prices in the United States. Then, I explain the two strategies the administration laid out today to attempt to use that authority. Finally, I articulate a number of unanswered questions the administration will need to resolve...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Congress / White House, Govt Agencies, HHS, Insurance, Patient / Consumer, Pharma, Provider, Regulations
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
AstraZeneca plans independent drug supply chains for US and China, CEO says
Digital Platforms Streamline Medication Access and Delivery
Pharma Pulse 3/27/24: Patients Hate ‘Forever’ Drugs—Is Wegovy Different? Low Melatonin Can Increase Risk of Neurological Disorders & more
Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Share This Article